Once again serum NM23-H1 levels were significantly higher in patients with all hematologic malignancies tested than in normal/healthy controls (Figure 2(a)), and an elevated serum NM23-H1 protein concentration predicted a poor outcome of AML (Figure 2(b)) and various types of malignant lymphoma (Figure 2(c)) [11, 17–19, 32]. The gene discussed is NME1; the disease is lymphoma.